Zhang L, Du D, Wang L, et al. - This study found that topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors had promising treatment efficacy and safety in patients with atopic dermatitis (AD). Tofacitinib 2% BID, ruxolitinib 1.5% BID and delgocitinib 3% BID were found to be more effective than other JAK and PDE4 inhibitors.

• In total, 10 randomized controlled trials of topical JAK and PDE4 inhibitors with 4,689 patients were involved for analysis.

• Three topical JAK inhibitors and two topical PDE4 inhibitors were used.

• At 4 weeks of treatment, all JAK and PDE4 inhibitors had a higher IGA response than placebo.

• Tofacitinib 2% BID, ruxolitinib 1.5% BID and delgocitinib 3% BID, all with similar safety profiles, demonstrated favorable IGA response when compared with topical tacrolimus and corticosteroids.

• Tofacitinib 2% BID had the highest probability of achieving IGA response among all included JAK and PDE4 inhibitors, according to a ranking analysis.

• Furthermore, JAK and PDE4 inhibitors had a non-inferior safety profile when compared with placebo.